Walter Klemp, Chairman and CEO of Moleculin, expressed optimism regarding the upcoming data readout, stating, "We believe this upcoming data readout represents the most important milestone in our history to date. This is a critical achievement for Moleculin and, more importantly, for patients facing relapsed or refractory AML. Reaching the 45 subject mark brings us to the threshold of our first meaningful look at MIRACLE data. Based on what we believe to be encouraging blinded results announced in February, we believe we are building real momentum toward what could be a transformative outcome."
The trial protocol allows for early unblinding of data after the first 45 subjects complete treatment, which is expected to yield an initial dataset of approximately 30 patients treated with AnnAraC and 15 patients in the control arm receiving cytarabine plus placebo. The interim readout is expected to provide critical insights into efficacy, safety, and dose optimization as the study progresses toward its Phase 3 portion.
Moleculin's ongoing MIRACLE trial is a global, adaptive Phase 2B/3 study designed to evaluate AnnAraC across multiple countries. The company has reported early signals of efficacy, with a preliminary blinded composite complete remission rate of 40% among the first 30 patients enrolled in the trial. This is particularly notable given that many of these patients had previously failed venetoclax-based therapies and exhibited adverse genetic markers typically associated with poor outcomes.
The upcoming unblinding of the first 45 subjects is anticipated to be a strong indicator of the potential for Annamycin to become a next-generation anthracycline, which has long been sought by medical science. The company is also advancing toward a potential accelerated approval pathway based solely on the Complete Remission primary endpoint. As the trial progresses, Moleculin Biotech continues to build momentum in its oncology pipeline, which includes ongoing and planned studies targeting various difficult-to-treat tumors.
